Ohtuvayre™is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients ...

Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the ...

Verona Pharma (NASDAQ:VRNA)'s stock has reached an unprecedented peak, setting an all-time high at $56.49. This milestone underscores a remarkable period of growth for the $4.49 billion ...

Verona Pharma reported a total of $36 million in net revenue for the fourth quarter of 2024, solely attributed to sales of Ohtuvayre (ensifentrine), its FDA-approved treatment for chronic ...

and now Verona has revealed the drug made approximately $36 million in the final three months of 2024, off more than 16,000 prescriptions. Chief executive David Zaccardelli said Ohtuvayre was off ...

Verona has been assigned a unique J-code for Ohtuvayre, J7601, which took effect at the beginning of this month, the analyst tells investors in a research note. The firm believes this should ...

And I predict that 2025 will be another momentous year for Summit. Summit already owned the license to market ivonescimab in the U.S., Canada, Europe, and Japan before Akeso's news broke. The company ...

David Zaccardelli, Pharm. D., President and Chief Executive Officer of Verona Pharma, said: "We are very pleased that Ohtuvayre TM is available to help patients still experiencing daily COPD symptoms.